Date: 2013-03-06
Type of information: Licensing agreement
Compound: fentanyl sublingual tablets
Company: Grunenthal (Germany) Ethypharm (France)
Therapeutic area: Cancer - Oncology - CNS diseases
Type agreement: licensing
commercialisation
distribution
supply
Action mechanism:
Disease: cancer pain
Details: Grünenthal Group has concluded an exclusive license, distribution and supply agreement with Ethypharm. The agreement allows the company to commercialize Ethypharm\'s fentanyl sublingual tablets for the treatment of breakthrough cancer pain in selected European markets. With the in-licensing of the product, the Grünenthal Group can now offer patients an additional pain treatment option and establishes a strategic extension to its own pain product portfolio.
The license agreement between Grünenthal and Ethypharm includes the rights for the following markets: France, UK, Belgium, Netherlands, Sweden and Denmark.
Financial terms:
Latest news:
